ClinVar Miner

Submissions for variant NM_001351834.2(ATM):c.381del (p.Thr127_Val128insTer) (rs587781831)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000130118 SCV000184949 pathogenic Hereditary cancer-predisposing syndrome 2018-05-23 criteria provided, single submitter clinical testing Alterations resulting in premature truncation (e.g.reading frame shift, nonsense)
GeneDx RCV000478446 SCV000566915 pathogenic not provided 2018-08-29 criteria provided, single submitter clinical testing This deletion of one nucleotide is denoted ATM c.381delA at the cDNA level and p.Val128Ter (V128X) at the protein level. The normal sequence, with the base that is deleted in brackets, is ATAC[delA]GTGA. The deletion creates a nonsense variant, which changes a Valine to a premature stop codon (GTG>TGA), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. ATM c.381delA, previously reported as 380delA, has been observed in the homozygous state and compound heterozygous state in individuals with Ataxia telangiectasia (Neubauer 2002, Babaei 2005, Broccoletti 2011). This variant is considered pathogenic.
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000478446 SCV000602573 pathogenic not provided 2017-06-13 criteria provided, single submitter clinical testing The c.381delA variant has been previously reported in association with ataxia telangiectasia in multiple unrelated families (Mitui 2005, and Babaei 2005). The c.381delA variant creates a frameshift in the ATM protein at codon 128 in exon 5 which results in a premature termination codon and is predicted to result in a truncated or absent protein product. It is absent from general population databases such as 1000 Genomes, NHLBI GO Exome Sequencing Project (ESP) , and the Exome Aggregation Consortium (ExAC) browser but has been reported to ClinVar (Variation ID: 141546). Based on these observations, the c.381delA variant has been classified as pathogenic.
Color RCV000130118 SCV000687504 pathogenic Hereditary cancer-predisposing syndrome 2020-05-14 criteria provided, single submitter clinical testing
Invitae RCV000627887 SCV000748771 pathogenic Ataxia-telangiectasia syndrome 2019-11-18 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Val128*) in the ATM gene. It is expected to result in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been reported to co-occur with different pathogenic ATM variants in individuals affected with ataxia-telangiectasia (A-T) (PMID: 16266405, 15843990, 25502423, 25614872 ). This variant is also known as c.380delA and c.381_381delA in the literature. ClinVar contains an entry for this variant (Variation ID: 141546). Experimental studies in heterozygous cell lines have suggested that this sequence change leads to reduced ATM protein following exposure to radiation (PMID: 14970866). Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). For these reasons, this variant has been classified as Pathogenic.
Counsyl RCV000627887 SCV000791538 pathogenic Ataxia-telangiectasia syndrome 2017-05-18 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000627887 SCV000915496 pathogenic Ataxia-telangiectasia syndrome 2018-08-14 criteria provided, single submitter clinical testing The ATM c.381delA (p.Val128Ter) variant is a stop-gained variant predicted to result in premature termination of the protein. Across a selection of the available literature, the p.Val128Ter variant has been found in at least six individuals with ataxia-telangiectasia, all in a compound heterozygous state (Babaei et al. 2005; Mitui et al. 2005; Quarantelli et al. 2013; Podralska et al. 2014). Control data are not available for this variant, which is reported at a frequency of 0.000009 in the European (non-Finnish) population of the Genome Aggregation Database. Based on the collective evidence and the potential impact of frameshift variants, the p.Val128Ter variant is classified as pathogenic for ataxia-telangiectasia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Blueprint Genetics RCV000478446 SCV000927283 likely pathogenic not provided 2017-06-06 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000627887 SCV001360415 pathogenic Ataxia-telangiectasia syndrome 2019-04-01 criteria provided, single submitter clinical testing Variant summary: ATM c.381delA (p.Val128X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 4.1e-06 in 246028 control chromosomes (gnomAD). c.381delA has been reported in the literature in individuals affected with Ataxia-Telangiectasia (Broccoletti_2011, Micol_2011, Mitui_2005). These data indicate that the variant is likely to be associated with disease. Experimental evidence evaluating an impact on protein function, demonstrated the variant to result in an overall reduced ATM protein level, mRNA level and cell survival after exposure to ionizing radiation (Fernet_2004). Six ClinVar submissions from clinical diagnostic laboratories (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Biochemical Molecular Genetic Laboratory,King Abdulaziz Medical City RCV000627887 SCV001133023 pathogenic Ataxia-telangiectasia syndrome 2019-09-26 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.